Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 3097-3099

  Murakami, Kazunari ^a   Okimoto, Tadayoshi ^a   Kodama, Masaaki ^a   Tanahashi, Jin ^a   Fujioka, Toshio ^a   Ikeda, Fumiaki ^b   Muraoka, Hiroe ^b   Takigawa, Motoko ^b   Saika, Takeshi ^b   Hasegawa, Miyuki ^b   Kobayashi, Intetsu ^c  

^a OITA UNIVERSITY   (Japan)

^b LSI MEDIENCE CORPORATION   (Japan)

^c TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GARENOXACIN; LEVOFLOXACIN; SITAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG ACTIVITY; GENE MUTATION; GYRA GENE; HELICOBACTER PYLORI; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; DNA GYRASE; FLUOROQUINOLONES; HELICOBACTER PYLORI; MICROBIAL SENSITIVITY TESTS; MUTATION; OFLOXACIN;

EID: 67649994346     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01552-08     Document Type: Article

References (16)

1. Akasaka, T., S. Kurosaka, Y. Uchida, M. Tanaka, K. Sato, and I. Hayakawa. 1998. Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases. Antimicrob. Agents Chemother. 42:1284-1287.
2. Bogaerts, P., C. Berhin, H. Nizet, and Y. Glupczynski. 2006. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter 11:441-445.
3. Chey, W. D., B. C. Wong, and the Practice Parameters Committee of the American College of Gastroenterology. 2007. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am. J. Gastroenterol. 102:1808-1825.
4. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A7, 7th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; 18th informational supplement. M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Fung-Tomc, J. C., B. Minassian, B. Kolek, E. Huczko, L. Aleksunes, T. Stickle, T. Washo, E. Gradelski, L. Valera, and D. P. Bonner. 2000. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob. Agents Chemother. 44:3351-3356.
7. Gisbert, J. P., and F. Morena. 2006. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment. Pharmacol. Ther. 23:35-44.
8. Kobayashi, I., K. Murakami, M. Kato, S. Kato, T. Azuma, S. Takahashi, N. Uemura, T. Katsuyama, Y. Fukuda, K. Haruma, M. Nasu, and T. Fujioka. 2007. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J. Clin. Microbiol. 45:4006-4010.
9. Kulsuntiwong, P., C. Chomvarin, K. Chaicumpar, W. Namwat, W. Kaewkes, P. Mairlang, and A. Sangchan. 2008. Antimicrobial susceptibility of Helicobacter pylori isolated from gastric biopsies in dyspeptic patients. Southeast Asian J. Trop. Med. Public Health 39:1102-1109.
10. Malfertheiner, P., F. Megraud, C. O'Morain, F. Bazzoli, E. El-Omar, D. Graham, R. Hunt, T. Rokkas, N. Vakil, and E. J. Kuipers. 2007. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56:772-781.
11. Mégraud, F. 2004. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53:1374-1384.
12. Nishizawa, T., H. Suzuki, K. Kurabayashi, T. Masaoka, H. Muraoka, M. Mori, E. Iwasaki, I. Kobayashi, and T. Hibi. 2006. Gatifloxacin resistance and mutations in gyrA after unsuccessful Helicobacter pylori eradication in Japan. Antimicrob. Agents Chemother. 50:1538-1540.
13. Nista, E. C., M. Candelli, M. A. Zocco, F. Cremonini, V. Ojetti, R. Finizio, C. Spada, G. Cammarota, G. Gasbarrini, and A. Gasbarrini. 2006. Levo-floxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am. J. Gastroenterol. 101:1985-1990.
14. Romano, M., M. R. Iovene, M. I. Russo, A. Rocco, R. Salerno, D. Cozzolino, A. P. Pilloni, M. A. Tufana, and G. Nardone. 2008. Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates. J. Clin. Pathol. 61:1112-1115.
15. Sato, K., K. Hoshino, M. Tanaka, I. Hayakawa, and Y. Osada. 1992. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob. Agents Chemother. 36:1491-1498.
16. Shirasaka, D., N. Aoyama, I. Miki, Y. Matsumoto, H. Miyaji, M. Toyoda, T. Mitani, Y. Morita, T. Tamura, and T. Azuma. 2006. The efficiency and safety of second-eradication therapy for Helicobacter pylori with metronidazole and levofloxacin. J. Gastroenterol. 103S:782. (In Japanese.)